trending Market Intelligence /marketintelligence/en/news-insights/trending/SbWokrbokRav4FvrR_bkyg2 content esgSubNav
In This List

Thermo Fisher's Zika diagnosis kit gets emergency FDA authorization

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Thermo Fisher's Zika diagnosis kit gets emergency FDA authorization

The U.S. Food and Drug Administration authorized the emergency use of Thermo Fisher Scientific Inc.'s Zika virus diagnosis kit.

The authorization for the company's TaqPath Zika kit only covers the diagnosis of that particular virus and is not meant to be used for the diagnosis of any other infection.

It has not been FDA-cleared or approved and can only be used by certified laboratories.